Literature DB >> 18813015

Data analysis methods and the reliability of analytic epidemiologic research.

Ross L Prentice1.   

Abstract

Publications that compare randomized controlled trial and cohort study results on the effects of postmenopausal estrogen-plus-progestin therapy are reviewed. The 2 types of studies agree in identifying an early elevation in coronary heart disease risk, and a later developing elevation in breast cancer risk. Effects among women who begin hormone therapy within a few years after the menopause may be comparatively more favorable for coronary heart disease and less favorable for breast cancer. These analyses illustrate the potential of modern data analysis methods to enhance the reliability and interpretation of epidemiologic data.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18813015      PMCID： PMC2711000          DOI： 10.1097/EDE.0b013e318188e83b

Source DB:  PubMed          Journal:  Epidemiology        ISSN： 1044-3983            Impact factor:   4.822


  19 in total

Review 1.  Statistical issues arising in the Women's Health Initiative.

Authors:  Ross L Prentice; Mary Pettinger; Garnet L Anderson
Journal:  Biometrics       Date:  2005-12       Impact factor: 2.571

2.  Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy.

Authors:  Marcia L Stefanick; Garnet L Anderson; Karen L Margolis; Susan L Hendrix; Rebecca J Rodabough; Electra D Paskett; Dorothy S Lane; F Allan Hubbell; Annlouise R Assaf; Gloria E Sarto; Robert S Schenken; Shagufta Yasmeen; Lawrence Lessin; Rowan T Chlebowski
Journal:  JAMA       Date:  2006-04-12       Impact factor: 56.272

3.  Effects of conjugated equine estrogen on stroke in the Women's Health Initiative.

Authors:  Susan L Hendrix; Sylvia Wassertheil-Smoller; Karen C Johnson; Barbara V Howard; Charles Kooperberg; Jacques E Rossouw; Maurizio Trevisan; Aaron Aragaki; Alison E Baird; Paul F Bray; Julie E Buring; Michael H Criqui; David Herrington; John K Lynch; Stephen R Rapp; James Torner
Journal:  Circulation       Date:  2006-05-15       Impact factor: 29.690

4.  Combined postmenopausal hormone therapy and cardiovascular disease: toward resolving the discrepancy between observational studies and the Women's Health Initiative clinical trial.

Authors:  Ross L Prentice; Robert Langer; Marcia L Stefanick; Barbara V Howard; Mary Pettinger; Garnet Anderson; David Barad; J David Curb; Jane Kotchen; Lewis Kuller; Marian Limacher; Jean Wactawski-Wende
Journal:  Am J Epidemiol       Date:  2005-07-20       Impact factor: 4.897

5.  Observational studies analyzed like randomized experiments: an application to postmenopausal hormone therapy and coronary heart disease.

Authors:  Miguel A Hernán; Alvaro Alonso; Roger Logan; Francine Grodstein; Karin B Michels; Walter C Willett; Joann E Manson; James M Robins
Journal:  Epidemiology       Date:  2008-11       Impact factor: 4.822

6.  Combined analysis of Women's Health Initiative observational and clinical trial data on postmenopausal hormone treatment and cardiovascular disease.

Authors:  Ross L Prentice; Robert D Langer; Marcia L Stefanick; Barbara V Howard; Mary Pettinger; Garnet L Anderson; David Barad; J David Curb; Jane Kotchen; Lewis Kuller; Marian Limacher; Jean Wactawski-Wende
Journal:  Am J Epidemiol       Date:  2006-02-16       Impact factor: 4.897

7.  Conjugated equine estrogens and breast cancer risk in the Women's Health Initiative clinical trial and observational study.

Authors:  Ross L Prentice; Rowan T Chlebowski; Marcia L Stefanick; Joann E Manson; Robert D Langer; Mary Pettinger; Susan L Hendrix; F Allan Hubbell; Charles Kooperberg; Lewis H Kuller; Dorothy S Lane; Anne McTiernan; Mary Jo O'Sullivan; Jacques E Rossouw; Garnet L Anderson
Journal:  Am J Epidemiol       Date:  2008-04-29       Impact factor: 4.897

8.  Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial.

Authors:  Jacques E Rossouw; Garnet L Anderson; Ross L Prentice; Andrea Z LaCroix; Charles Kooperberg; Marcia L Stefanick; Rebecca D Jackson; Shirley A A Beresford; Barbara V Howard; Karen C Johnson; Jane Morley Kotchen; Judith Ockene
Journal:  JAMA       Date:  2002-07-17       Impact factor: 56.272

9.  Estrogen plus progestin therapy and breast cancer in recently postmenopausal women.

Authors:  Ross L Prentice; Rowan T Chlebowski; Marcia L Stefanick; Joann E Manson; Mary Pettinger; Susan L Hendrix; F Allan Hubbell; Charles Kooperberg; Lewis H Kuller; Dorothy S Lane; Anne McTiernan; Mary Jo O'Sullivan; Jacques E Rossouw; Garnet L Anderson
Journal:  Am J Epidemiol       Date:  2008-03-27       Impact factor: 4.897

10.  Conjugated equine estrogens and coronary heart disease: the Women's Health Initiative.

Authors:  Judith Hsia; Robert D Langer; Joann E Manson; Lewis Kuller; Karen C Johnson; Susan L Hendrix; Mary Pettinger; Susan R Heckbert; Nancy Greep; Sybil Crawford; Charles B Eaton; John B Kostis; Pat Caralis; Ross Prentice
Journal:  Arch Intern Med       Date:  2006-02-13
View more
  2 in total

1.  Hormone replacement therapy in females can decrease the risk of lung cancer: a meta-analysis.

Authors:  Yanwen Yao; Xiaoling Gu; Juehua Zhu; Dongmei Yuan; Yong Song
Journal:  PLoS One       Date:  2013-08-14       Impact factor: 3.240

2.  Point: incident exposures, prevalent exposures, and causal inference: does limiting studies to persons who are followed from first exposure onward damage epidemiology?

Authors:  Jan Vandenbroucke; Neil Pearce
Journal:  Am J Epidemiol       Date:  2015-10-26       Impact factor: 4.897
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.